Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aryloxyalkanoate dioxygenase (AAD) is a class of bacterial enzymes, most notably AAD-1 and AAD-12, that are utilized in agricultural biotechnology to confer herbicide resistance to transgenic crops [4, 6]. These enzymes belong to the non-heme Fe(II) and alpha-ketoglutarate-dependent dioxygenase superfamily and were originally identified in soil bacteria such as Sphingobium herbicidivorans and Delftia acidovorans [2, 6]. AAD enzymes catalyze the oxygenolytic cleavage of the ether bond in various aryloxyalkanoate herbicides, including the synthetic auxin 2,4-dichlorophenoxyacetic acid (2,4-D) and aryloxyphenoxypropionate (fop) herbicides [4, 7]. By converting these active herbicides into non-toxic metabolites like phenols and glyoxylate, AAD allows crops such as corn, soybean, and cotton to survive applications of these chemicals [4, 13]. This technology is a key component of the Enlist weed control system, designed to manage glyphosate-resistant weeds [4, 10]. While AAD is not a human therapeutic target, its study provides critical insights into enzyme-substrate specificity and the evolution of metabolic pathways for xenobiotic degradation [6, 11]. The enzyme's activity is dependent on the presence of ferrous iron and alpha-ketoglutarate as cofactors [2, 8]. Safety assessments have shown that AAD proteins have low potential for toxicity or allergenicity in humans and minimal impact on plant endogenous metabolism [9, 13]. The deployment of AAD-containing crops has significantly expanded the options for integrated weed management in modern agriculture [4, 10]. Ongoing research continues to explore the structural basis for the broad substrate range and enantioselectivity of different AAD variants [6, 11].
Enzymatic degradation of herbicide substrates via oxidative dealkylation [2, 4, 10]
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aryloxyalkanoate dioxygenase (AAD).